Evidence map›Paper›PMID 27841740›Full record

ArticleRadiation research2016

IPW-5371 Proves Effective as a Radiation Countermeasure by Mitigating Radiation-Induced Late Effects.

Christopher Rabender, Eleonora Mezzaroma, Adolfo G Mauro, Ramesh Mullangi, Antonio Abbate, Mitchell Anscher, Barry Hart, Ross Mikkelsen

Open access · greenAbstract read
In one paragraph

Article in Radiation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Biomarkers to Predict Lethal Radiation Injury to the Rat Lung.International journal of molecular sciences · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. [Radiation-Induced Heart Disease: Current Status and Challenges].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022
    Review
  14. Review
  15. Review
  16. An overview of radiation-induced heart disease.Radiation oncology journal · 2022
    Article
  17. Article
  18. Article
  19. Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside.Clinical research in cardiology : official journal of the German Cardiac Society · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Christopher Rabendera   Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia 23298.
Eleonora Mezzaromab   Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia 23298.
Adolfo G Maurob   Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia 23298.
Ramesh Mullangif   Jubilant Biosys Ltd., Yeshwanthpur, Bangalore-560022, Karnataka, India.
Antonio Abbateb   Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia 23298.
Mitchell Anschera   Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia 23298.
Barry Harte   Innovation Pathways, Palo Alto, California 94301.
Ross Mikkelsena   Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia 23298.
Virginia Commonwealth University · USInnovation Pathways · USJubilant Life Sciences (India) · IN

Funding

Universiity of Rochester Center for Medical Countermeasures against RadiationU19AI091036 · NIAID · UNIVERSITY OF ROCHESTER · PI WILLIAMS, JACQUELINE PATRICIA · 2010 to 2014
$15.6M
NIAID NIH HHS U19 AI091036
6 · The paper itself

Abstract

There is an ongoing and significant need for radiation countermeasures to reduce morbidities and mortalities associated with exposure of the heart and lungs from a radiological or nuclear incidents. Radiation-induced late effects occur months to years after exposure, stemming from significant tissue damage and remodeling, resulting in fibrosis and loss of function. TGF-β is reported to play a role in both pulmonary and cardiac fibrosis. We investigated the ability of a small molecule TGF-β receptor 1 inhibitor, IPW-5371, to mitigate the effects of thoracic irradiation in C57L/J mice, a murine model that most closely resembles that observed in humans in the induction of fibrosis and dose response. To simulate a radiological event, radiation was administered in two doses: 5 Gy total-body irradiation (eliciting a whole-body response) and immediately after that, a thoracic "top-up" of 6.5 Gy irradiation, for a total dose of 11.5 Gy to the thorax. IPW-5371 was administered once daily, orally, starting 24 h postirradiation for 6 or 20 weeks at a dose of 10 mg/kg or 30 mg/kg. Animals were monitored for a period of 180 days for survival, and cardiopulmonary injury was assessed by echocardiography, breathing rate and arterial oxygen saturation. Exposure of the thorax (11.5 Gy) induced both pulmonary and cardiac injury, resulting in a reduced life span with median survival of 135 days. IPW-5371 treatment for 6 weeks, at both 10 mg/kg and 30 mg/kg, delayed disease onset and mortality, with median survival of 165 days. Twenty weeks of IPW-5371 treatment at 30 mg/kg preserved arterial O

Indexed as

AnimalsCardiomyopathiesCollagenFemaleHalf-LifeLungMaleMiceMyocardiumProtein Serine-Threonine KinasesRadiation Injuries, ExperimentalRadiation-Protective AgentsReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IRespirationSignal TransductionCollagenProtein Serine-Threonine KinasesRadiation-Protective AgentsReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type ITransforming Growth Factor beta

Identifiers

PMID27841740
PMCPMC5278768
OpenAlexW2523649561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.